Stevanato Group (NYSE:STVN) Trading Down 0.3% – Should You Sell?

Shares of Stevanato Group S.p.A. (NYSE:STVN) dropped 0.3% during mid-day trading on Monday . The company traded as low as €22.79 ($23.49) and last traded at €23.23 ($23.95). Approximately 32,392 shares changed hands during trading, a decline of 94% from the average daily volume of 500,132 shares. The stock had previously closed at €23.31 ($24.03).

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Wolfe Research began coverage on Stevanato Group in a research report on Friday, December 13th. They issued an “outperform” rating and a $28.00 price objective for the company. Morgan Stanley restated an “equal weight” rating and set a $23.00 price objective (down from $24.00) on shares of Stevanato Group in a research report on Tuesday, December 3rd. Finally, Bank of America lifted their target price on shares of Stevanato Group from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, December 13th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of €28.60 ($29.48).

Stevanato Group Price Performance

The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.21 and a current ratio of 1.81. The stock’s 50 day simple moving average is €19.87 and its two-hundred day simple moving average is €19.73. The firm has a market capitalization of $6.64 billion, a PE ratio of 47.81, a price-to-earnings-growth ratio of 10.49 and a beta of 0.59.

Stevanato Group (NYSE:STVN) last released its quarterly earnings data on Tuesday, November 5th. The company reported €0.12 ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of €0.13 ($0.13) by (€0.01) (($0.01)). The firm had revenue of €277.90 million for the quarter, compared to analyst estimates of €274.36 million. Stevanato Group had a return on equity of 9.86% and a net margin of 10.47%. Stevanato Group’s revenue for the quarter was up 2.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.16 earnings per share. On average, sell-side analysts forecast that Stevanato Group S.p.A. will post 0.5 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. nVerses Capital LLC purchased a new position in shares of Stevanato Group during the 3rd quarter worth approximately $84,000. Raymond James Trust N.A. boosted its position in shares of Stevanato Group by 18.7% during the second quarter. Raymond James Trust N.A. now owns 10,239 shares of the company’s stock worth $188,000 after buying an additional 1,613 shares during the period. Hardy Reed LLC grew its stake in shares of Stevanato Group by 8.2% in the third quarter. Hardy Reed LLC now owns 11,077 shares of the company’s stock valued at $222,000 after buying an additional 840 shares in the last quarter. Lindenwold Advisors INC raised its holdings in shares of Stevanato Group by 13.5% in the 3rd quarter. Lindenwold Advisors INC now owns 11,930 shares of the company’s stock valued at $239,000 after buying an additional 1,415 shares during the period. Finally, Oppenheimer Asset Management Inc. lifted its stake in Stevanato Group by 59.2% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 11,941 shares of the company’s stock worth $219,000 after acquiring an additional 4,441 shares in the last quarter.

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.